🇺🇸 US

REGN revenue, net income and debt history (Regeneron Pharmaceuticals, Inc.)

Quick answer

Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $14.34B and net income of $4.50B for the fiscal year ended 2025-12-31, up 1.0% from $14.20B the year before, per its 10-K filed with the SEC on 2026-02-04. Long-term debt stood at $1.99B.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$14.34B$4.50B$1.99B
2024 (FY ending 2024-12-31)$14.20B$4.41B$1.98B
2023 (FY ending 2023-12-31)$13.12B$3.95B$1.98B
2022 (FY ending 2022-12-31)$12.17B$4.34B$1.98B
2021 (FY ending 2021-12-31)$16.07B$8.08B$1.98B
2020 (FY ending 2020-12-31)$8.50B$3.51B$1.98B
2019 (FY ending 2019-12-31)$6.56B$2.12B$0.0M
2018 (FY ending 2018-12-31)$5.15B$2.44B—
2017 (FY ending 2017-12-31)$5.87B$1.20B—
2016 (FY ending 2016-12-31)$4.86B$895.5M—

Related

Last updated 2026-10-16. Data only, not financial or tax advice.